ERAS NASDAQ
Erasca, Inc.
1W: +12.0%
1M: -46.4%
3M: -7.4%
YTD: +223.4%
1Y: +807.0%
3Y: +308.8%
$11.24
-0.36 (-3.15%)
Weekly Expected Move ±28.7%
$4
$7
$10
$13
$16
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
2 bullish
0 neutral
2 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (87)
Erasca, Inc. (ERAS) Shares Crater 48%, Wiping Out $2.8 Billion of Market Cap; Hagens Berman Investigating Intellectual Property Questions Regarding Lead Asset
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
ERAS SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
Erasca Reports First Quarter 2026 Business Updates and Financial Results
ERAS Investors Have Opportunity to Join Erasca, Inc. Fraud Investigation with the Schall Law Firm
Erasca, Inc. Investors Should Contact Block & Leviton LLP to Learn More About Securities Fraud Investigation
Revolution Medicines wins FDA nod to provide early access to cancer therapy
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results
ERAS stock slumps against RVMD rally — analyst stays bullish - MSN
Erasca Shares Plunge 48% After Trial Patient Death, Patent Dispute Emerges
Why Erasca Stock Is Tumbling Despite Drug Hopes - TipRanks
Erasca stock sinks 50% after patient death in drug trial
Patient Death Drags Erasca (ERAS) Shares by 48%
Patient Death Drags Erasca (ERAS) Shares by 48% - Yahoo Finance
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Stock Market Today, April 28: Erasca Plunges After Patient Death in Early Cancer Drug Trial
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.
Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off. - Barron's
Erasca (NASDAQ: ERAS) details 2026 virtual meeting and executive pay - Stock Titan
Why Erasca, Up 415% This Year Amid Revolution-Tied Furor, Just Lost Half Its Value
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 - Slideshow (NASDAQ:ERAS) 2026-04-28 - Seeking Alpha
Erasca Shares Fall After Preliminary Phase 1 Dose Escalation Data
Erasca (ERAS) Stock Crashes 50% After Patient Death in Cancer Drug Trial - CoinCentral
12 Health Care Stocks Moving In Tuesday's Intraday Session
Crude Oil Gains Over 3%; General Motors Earnings Top Views
Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Erasca, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors to Contact the Firm to Possibly Recover Losses
ERAS Stock Slides As Legal And Clinical Risks Rattle Traders - StocksToTrade
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings
Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday?
ERAS stock slumps nearly 40% after-hours: Fine print in 'positive' cancer trial reveals treatment-related death - MSN
Rambus Posts Downbeat Q1 Earnings, Joins Erasca, Spotify, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy
Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy - Seeking Alpha
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death - Stocktwits
Erasca Shares Phase 1 ERAS-0015 Data: 62% NSCLC Response, ctDNA Clearance Signals
12 Health Care Stocks Moving In Monday's After-Market Session
Erasca stock tumbles 5% on cancer drug trial data - Investing.com
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
ERAS Stock Slides As Revolution Study Rattles Traders - StocksToTrade
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
Cancer drug developer Erasca sets 4:30 p.m. call on ERAS-0015 data - Stock Titan
ERAS Stock Price, Quote & Chart | ERASCA INC (NASDAQ:ERAS) - ChartMill
Erasca (ERAS) Hits 4-Year High Ahead of ERAS-0015 Trial Results
What’s Driving Erasca (ERAS)’s Nearly 355% YTD Return
Erasca (NASDAQ:ERAS) Hits New 1-Year High – Should You Buy?
Erasca (ERAS) Among the Best Performing Stocks of Q1 2026 to Watch for Q2
JPMorgan Chase & Co. Has $2.77 Million Stock Holdings in Erasca, Inc. $ERAS
Ebun Garner Sells 80,000 Shares of Erasca (NASDAQ:ERAS) Stock
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't
Erasca CMO's Direct Stake Hit Zero. Her Options Position Didn't
Top performing mid-cap stocks YTD as volatility hits markets
Assessing Erasca (ERAS) Valuation After ERAS-0015 Licensing Win And Data Anticipation
$ERAS stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
Okta To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Friday
Tango rises after Q4 results, clinical pact with Erasca
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat
Stock Traders Buy Large Volume of Erasca Call Options (NASDAQ:ERAS)
Erasca to Present at Upcoming Conferences in February
Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Erasca Announces Pricing of Upsized Public Offering of Common Stock
Erasca, Inc. (NASDAQ:ERAS) Sees Large Increase in Short Interest
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
Erasca Stock Surges 42% in a Week: Here's What You Should Know
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
Erasca Insider Sells $671K as Stock Jumps 189% This Past Year
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
Ebun Garner Sells 120,000 Shares of Erasca (NASDAQ:ERAS) Stock
What's Going With Cancer Biotech Erasca Stock On Thursday?
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
Hallador Energy Advances Expansion into Natural Gas Power Generation through ERAS Application
Erasca to Present at the 8th Annual Evercore Healthcare Conference